Overview

Metronomic Docetaxel and Bevacizumab in Patients With Small Cell Lung Cancer

Status:
Withdrawn
Trial end date:
2012-08-01
Target enrollment:
Participant gender:
Summary
This trial will evaluate the efficacy and safety of metronomic docetaxel and bevacizumab combination in patients with pretreated, advanced small cell lung cancer.
Phase:
Phase 2
Details
Lead Sponsor:
University Hospital of Crete
Treatments:
Bevacizumab
Docetaxel